Radiosensitivity, while not always a non-fashionable topic, is one that cannot be ignored, and has continued to draw the attention of radiation oncologists. Radioresistence is one of the major reasons for radiation therapy failure, and novel ways for overcoming are in need.

With the development of radiation physics, cutting edge technologies have pushed radiation therapy into the era of "precision medicine". Radiation biology, for its part, has also progressed in kind. For example, nanoparticles of radiosensitizer are on the way to in overcoming radioresistance. Biomarkers for response prediction to radiotherapy are helping physicians in decision making. More excitingly, the combination of immunotherapy and radiotherapy has shown very promising results in clinical studies!

This book, *Key Leaders' Opinion on Precision Radiation Oncology*, reports on many of the new, important contributions to the progress of radiation oncology by key opinion leaders. This is a very comprehensive series that summarize the current excitement in the field of clinical radiobiology and translational radiotherapy. The book will provide clinical oncologists, radiation biologists and other specialists an excellent update, and will stimulate new basic and clinical research activities.

We believe that the enthusiastic collaboration of experts in this field is essential to accelerating research in radiation oncology, and will eventually make progresses.



Zhen Zhang, MD
Professor of Radiation Oncology,
Chiar of the Department of Radiation Oncology,
Fudan University Shanghai Cancer Center,
270 Dongan Road, Shanghai, China